News

Nvidia Faces Challenges: EPS and Revenue Trends Revealed

Nvidia Faces Challenges: EPS and Revenue Trends Revealed

Nvidia Faces Challenges: Understanding Recent EPS and Revenue Trends

Nvidia (NASDAQ: NVDA) experienced a notable drop of 6% recently, which raised eyebrows following CEO Jensen Huang's optimistic speech at CES. It seems that the market was not entirely convinced by the excitement surrounding the new products mentioned, considering the significant trading volume of 347 million shares on that day.

This figure surpassed the average daily volume of 218 million shares, indicating a worrying 59% increase in volume, but to the downside. Such movements often signal that there may be underlying concerns regarding the company’s future performance.

Let’s delve into the forward EPS and revenue estimates for NVDA, as well as the recent revisions that could provide more context around its performance.

Insights into NVDA EPS Estimate Revisions

The fiscal year for NVDA is shaping up to be interesting, especially with the upcoming report scheduled for February. According to recent data, NVDA’s EPS estimates have seen substantial revisions over the past year:

  • A year ago, NVDA’s earnings per share (EPS) was projected at $2.08 for fiscal ’25. Yesterday's revised estimate stands at $2.95, reflecting a strong positive revision of 42% over the last 12 months.
  • In February of the previous year, the EPS outlook was $2.44, which has now increased by 21% to $2.95.
  • Back in May, it was estimated at $2.70, making the current revision $2.95 a positive adjustment of 9%.
  • Then in August, the forecast was at $2.82, leading to the existing estimate of $2.95, a 5% positive change.
  • Finally, in November, the EPS targeted figure remained at $2.95, illustrating no change in estimates over the last couple of months.

Looking ahead to fiscal ’26, the estimates indicate notable revisions as well:

  • Initially, the EPS for fiscal ’26 was estimated at $2.3 a year ago, but it has shot up to $4.43, marking a remarkable positive revision of 82%.
  • In February, it was at $2.98, which is now up to $4.43, signaling a 49% revision.
  • From May, the figures rose from $3.57 to $4.43, representing a 24% upward adjustment.
  • Again, from August at $3.97 to $4.43 reflects a 12% increase.
  • As of November, the estimate stayed steady at $4.43, showing no change.

Analyzing NVDA Revenue Revisions

Moving on to revenue estimates provides an equally illuminating perspective:

  • Last year, the initial revenue estimate for fiscal ’25 was $93.4 billion; however, this has been adjusted to $129.3 billion, a solid 38% increase.
  • In February of the previous year, revenue was estimated at $109.4 billion, which has also climbed to $129.3 billion, an 18% revision boost.
  • By May, the revenue projections were at $120.3 billion, which remains close to the current estimate of $129.3 billion, showing a 7.5% positive shift.
  • In August, the revenue figures rose from $124.8 billion to today's $129.3 billion, signaling a weaker adjustment of 4%.
  • As of November, the predictions stabilized as expected revenue estimates remained flat at $129.3 billion.

Observing the pattern of revenue estimates illustrates that the adjustments for fiscal ’25 have become less pronounced as the calendar year unfolds. This gradual decline in revision rates is crucial for a growth-centric company like Nvidia.

Conclusion: What Lies Ahead for Nvidia?

The end of fiscal ’25 is approaching on January 31, and the strength of revisions will determine implications for fiscal ’26 moving forward. Leadership guidance will play a pivotal role in reassuring investors amidst fluctuating market sentiments.

This article reflects my modest position in NVDA, especially given the recent market behavior, testing technical support levels. With the ongoing media buzz surrounding Nvidia, it's quite complex to maintain a larger stake in the stock. However, this is not intended to imply a bearish or bullish stance; it merely represents an examination of the figures surrounding the company.

Frequently Asked Questions

What contributed to Nvidia's recent 6% decline?

The decline came after an optimistic presentation by CEO Jensen Huang at CES, which raised concerns among investors regarding the company’s future performance.

How significant were the EPS revisions for Nvidia?

Nvidia's EPS estimates saw a positive revision of up to 82% for fiscal '26, showcasing strong growth expectations despite recent trading volume declines.

What are the implications of decreasing revenue estimate revisions?

Decreasing revisions may suggest a slowing growth momentum for Nvidia, which is critical for investor confidence in a high-growth stock.

How often does Nvidia report its financial results?

Nvidia typically reports its quarterly financial results in February, May, August, and November each year.

What is the focus for Nvidia looking ahead to fiscal '26?

The focus will be on guidance provided by the company's leadership, especially considering the recent trends in EPS and revenue estimates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Advocacy for Hiring Disabled Kidney Patients Gains Steam

Updated Category News Views 94

Making Jobs Accessible for Kidney Patients Well, things are stirring up on Capitol Hill, and it's high time, if you ask me. The American Association of Kidney Patients (AAKP) is rallying hard for a bipartisan bill that could change the landscape for folks grappling with kidney diseases and disabilities. You’ve got Reps Pete Sessions and Steny Hoyer pushing this American...

Continue Reading
First Citizens Surprises with Q3 Gains and Buyback Plan

Updated Category News Views 5

Unexpected Third Quarter Tailwinds for First Citizens There are days in this trading gig when a bank I'll barely sneeze at hits out of the park. First Citizens BancShares (NASDAQ:FCNCA) pulled off such a feat, wringing out a third-quarter 2026 performance that beat their own benchmarks. They threw $600 million back to shareholders in repurchased stocks while repaying an...

Continue Reading
Gentex Shares Tumble Amid Legal Investigation Concerns

Updated Category News Views 10

Gentex's Financial Outlook Takes a Hit Well, here we are again, catching another corporate hiccup. Gentex Corporation, or as ticker hounds know it, NASDAQ:GNTX, just pulled the rug out from its investors by chopping the top off its 2026 revenue guidance. Dropping to a floor it once considered a ceiling, $2.65 billion is now the most optimistic number they're pitching. No...

Continue Reading
A Game-Changer for Pediatric Diabetes: Novo's Awiqli®

Updated Category News Views 14

Breaking Through the Diabetes Treatment Wall From where I'm sitting, breakthrough approvals like Novo's Awiqli® hit the healthcare landscape with all the subtlety of a freight train. The FDA's green light for Awiqli® as the first once-weekly insulin for kids aged 10 and over with type 2 diabetes is a monumental shift in the treatment paradigm. We're talking about...

Continue Reading
Shanghai and Hamburg Celebrate 40 Years of Collaboration

Updated Category News Views 6

Strengthening the Bond: A Four-Decade Journey With fireworks of diplomacy and cooperation lighting up, Shanghai and Hamburg marked the 40th anniversary of their friendship with an ambition to deepen and broaden ties. These cities, separated by continents but united by their maritime spirit, decided to toast not just the past but also the future. This isn't just some fancy...

Continue Reading
Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

Updated Category News Views 24

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 66

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Astra Security Tackles PHP2Shell Vulnerabilities Head-On

Updated Category News Views 26

Unlocking the PHP Puzzle Hot off the press, Astra Security's stepping up to the plate with some freebie tools designed to sniff out and stamp out those pesky PHP2Shell vulnerabilities—CVE-2026-109618 and CVE-2026-109619. If you're not familiar, these suckers rate a whopping 9.2 on the CVSS v4.0 scale, and that means they got the potential to let remote code execution...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Lowcountry Kids to Get Free Helmets at Safety Events

Updated Category News Views 5

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

CoinW Showcases Its Innovations at Taipei Blockchain Week 2024

Updated Category News Views 261

CoinW's Impactful Presence at Taipei Blockchain Week 2024 At the forefront of innovation and security, CoinW, a globally recognized cryptocurrency exchange, recently showcased its vision for the future during Taipei Blockchain Week 2024 as a Gold Sponsor. The event, celebrated for fostering discussions on blockchain advancements, featured the launch of PropW, CoinW's...

Continue Reading
Bank of Åland Plc Seeks Trading Admission of New Covered Bonds

Updated Category News Views 170

Application for Trading Admission of Covered Bonds Bank of Åland Plc, also recognized as Ålandsbanken Abp, is taking an important step by applying for the admission of a new security to trading on Nasdaq Helsinki. This involves their recent issuance of covered bonds, which are highly regarded in the financial market. Details of the Covered Bonds Issue The primary...

Continue Reading
Simpson Manufacturing's Q3 Earnings Report Shows Challenges Ahead

Updated Category News Views 54

Simpson Manufacturing's Third Quarter Performance Simpson Manufacturing Co., Inc. (NYSE: SSD) recently announced its third-quarter earnings, and the results did not meet the expectations of analysts. This disappointing performance resulted in a 5% decline in shares during after-hours trading. The company's focus on producing wood construction products highlights the...

Continue Reading
Alvotech Faces Challenges in Biologics License Approval Process

Updated Category News Views 349

Overview of Biologics License Application Status Alvotech, a prominent biotech firm specializing in biosimilars, has recently updated the market regarding its application status for AVT05, a potential competitor to Simponi (golimumab). The company has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) highlighting certain...

Continue Reading
Replimune Group Faces Class Action Lawsuit Amid FDA Setback

Updated Category News Views 127

Replimune Group Faces Class Action Lawsuit Amid FDA Setback Pomerantz LLP has brought attention to a class action lawsuit involving Replimune Group, Inc. (NASDAQ: REPL). This legal action is relevant for investors who have experienced losses on their investments in the company. It's crucial for affected investors to be proactive and consider their options as they navigate...

Continue Reading